• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    This invention relates to bacterial mutants, in particular of Streptococcus agalactiae, which secrete capsular polysaccharide and methods of purifying bacterial capsular polysaccharides secreted from the culture medium. The extracted polysaccharides are useful for producing vaccines comprising the polysaccharides alone or conjugated to proteins.
    公开号:BE1022780B1
    申请号:E2015/5286
    申请日:2015-05-05
    公开日:2016-09-02
    发明作者:Evita Balducci；Francesco Berti；Valdemar Robert Janulczyk；Y Ros Immaculada Margarit；Chiara Toniolo
    申请人:Glaxosmithkline Biologicals S.A.；
    IPC主号:
    专利说明:

    PURIFICATION OF SECRETED POLYSACCHARIDES BY S. AGALACTIAE Field of the invention
    This invention relates to bacterial mutants, particularly Streptococcus agalactiae, which secrete a capsular polysaccharide and methods for purifying bacterial capsular polysaccharides secreted from the culture medium. The polysaccharides extracted are useful for producing vaccines comprising polysaccharides alone or conjugated to proteins.
    Context of the invention
    Over the past 25 years, conjugate vaccines, including bacterial capsular polysaccharides (cps) conjugated to carrier proteins, have been developed. Capsular polysaccharides are important immunogens found on the surface of bacteria involved in a variety of bacterial diseases. This characteristic has led them to become an important component in vaccine design. Since saccharides are T-independent antigens, cps are generally poorly immunogenic. Conjugation to a carrier protein can convert T-independent antigens to T-dependent antigens, thereby enhancing "memory" responses and allowing protective immunity to develop.
    Therefore, the most effective saccharide vaccines are based on glycoconjugates. Examples include Haemophilus influenzae type b conjugate vaccine (Hib), conjugate vaccines against Streptococcus pneumoniae and Neisseria meningitidis serotype C (MenC). Another bacterium for which conjugate vaccines have been described is Streptococcus agalactiae, also known as "Group B Streptococcus", or simply "GBS". The "B" in "GBS" refers to the Lancefield classification which is based on the antigenicity of a carbohydrate, called "carbohydrate C", which is soluble in the diluted acid. Lancefield identified 13 types of carbohydrate C (designated from A to 0) that could be serologically differentiated. The organisms that infect humans most often belong to groups A, B, D, and G. In group B, strains of Streptococcus agalactiae were subdivided into 10 serotypes (Ia, Ib, II, III, IV, V , VI, VII, VIII and IX) depending on the structure of their capsular polysaccharide. ,
    Streptococcus agalactiae group B causes serious diseases, including bacteremia and meningitis in immunocompromised individuals and newborns. There are two main types of GBS infections in the newborn: early-onset disease that occurs within 5 days of birth and manifests as bacteremia (sepsis or blood infection) and pneumonia (infection of lungs) and late-onset illness which occurs between one week and approximately three months after birth and is generally characterized by meningitis (infection of fluid and envelopes of the brain) although bacteremia and pneumonia may also occur. GBS colonizes the vagina of about 25% of young women and contracts vertically when the baby crosses the pelvic-genital tract. In colonized mothers, about 1% of vaginal babies will be infected at a mortality rate of between 50 and 70%.
    Investigations have been conducted on the development of GBS-based and polysaccharide-based vaccines. Conjugates of each of the capsular polysaccharides from GBS serotypes 1a, Ib, II, III, and V have been shown to be safe and immunogenic in humans. For example, vaccinating pregnant women with type III cps has been shown to reduce the incidence of late-onset meningitis - infants acquire protective antibodies by placental transfer and are passively immunized.
    Large scale production of capsular polysaccharide vaccines requires adequate supplies of purified capsular polysaccharides. Methods for isolating capsular polysaccharides from bacterial cells exist in the state of the art. For example, EP0038265 discloses a method for preparing antigenic polysaccharides which comprises phenolizing the fermentation broth to lyse the bacteria and release the polysaccharide into the fermentation broth. EP0302887 discloses the extraction of a type III GBS polysaccharide by the general technique of Jennings et al. (Canadian J. Biochem 58: 112-120 (1980)). EP1664319 discloses a method for producing a polysaccharide which comprises: a) using a cationic detergent to precipitate the polysaccharide or a portion of the contaminants from the supernatant to obtain a first polysaccharide fraction; b) using an alcohol to precipitate the polysaccharide from the first polysaccharide fraction and obtain a second polysaccharide fraction; c) subjecting the second precipitated polysaccharide fraction by addition of an alcohol in the presence of an anionic detergent, such that the alcohol is present at a concentration which is lower than the concentration at which the polysaccharide precipitates; d) precipitating the polysaccharide from the soluble fraction by adding an alcohol to obtain a polysaccharide precipitate; e) the dissolution of the polysaccharide precipitate and its submission to concentration and diafiltration. EP1828230 discloses a method for the heterologous expression and secretion of complex polysaccharides in non-pathogenic, non-invasive Gram-positive bacteria. EP1951887 and EP2004223 relate to novel strains of Staphylococcus aureus that produce capsular polysaccharide type 5 at higher levels than wild-type bacteria. EP1051506 discloses a method for purifying capsular polysaccharides from cell components and culture supernatants. The method uses an alkaline treatment to lyse the bacteria but it also causes the hydrolysis of the basic labile bond that connects the capsular polysaccharide to the cellular components and also deacetylates the N-acetyl groups.
    However, the above methods require many purification steps, made even more complex by adherence of the capsular polysaccharide to the cell wall. The object of the invention is therefore to provide improved capsular polysaccharide production methods that do not require bacterial lysis or enzymatic treatment to release the polysaccharide, thereby simplifying purification and increasing yield. Summary of the invention
    The inventors propose a simplified production process that makes it possible to obtain a capsular polysaccharide from the culture medium in amounts significantly greater than those that can be obtained previously. By extracting the capsular polysaccharide from the culture medium, the method avoids the need to inactivate and lyse the bacteria, thereby reducing the complexity of the process and the time required. Advantageously, the CpsA and CpsD mutants exhibit reduced virulence so that the risks associated with the manipulation of the bacteria are reduced.
    Similarly, avoiding the need for basic extraction results in increased operator safety while maintaining the immunogenicity of the extracted polysaccharides since the process avoids the deacetylation of N-acetyl groups. .
    Therefore, according to a first aspect of the invention, there is provided a method for producing a capsular polysaccharide from Streptococcus agalactiae comprising: culturing in a suitable culture medium of a CpsA or CpsD mutant and recovering the polysaccharide from the culture medium. The CpsA and CpsD mutants of the present invention show increased secretion of the capsular polysaccharide compared to the wild-type strain.
    In a second aspect according to the invention, there is provided a polysaccharide isolated from Streptococcus agalactiae in which the polysaccharide has a molecular weight, in particular an average molecular weight greater than 800 kDa, greater than 900 kDa, greater than 1000 kDa. , greater than 1100 kDa, greater than 1200 kDa, greater than 1300 kDa, greater than 1400 kDa, greater than 1500 kDa, greater than 1600 kDa, approximately 1700 kDa, in particular approximately 1758 kDa, or any intermediate range.
    Brief description of the Figures
    Figure 1: Membrane transfer by the "Dot blot" method with the capsular anti-polysaccharide monoclonal antibody 1a of the secreted capsular polysaccharide. CpsA mutants secreted significantly greater amounts of polysaccharide compared to wild-type bacteria (strain 515).
    Figure 2: CpsA mutants had significantly less capsular polysaccharide adhering to the surface of the bacterial cell compared to wild-type bacteria (strain 515).
    Figure 3: CpsA mutants secrete significantly greater amounts of capsular polysaccharide having a wider size range (kDa).
    4: Membrane transfer by the Dot blot method with the monoclonal anti-capsular polysaccharide antibody 1a of the capsular polysaccharide secreted. CpsD mutants secreted significantly greater amounts of polysaccharide compared to wild-type bacteria (strain 515). Among the mutants given as examples, K49 and ΔΡ-tyr secreted higher amounts both with respect to the wild-type and to ACpsD. Therefore, the preferred mutations are those occurring at the active site of autokinase.
    Figure 5: CpsD mutants secrete significantly greater amounts of capsular polysaccharide having a size greater than that of capsular polysaccharides secreted by wild type strain 515 (kDa).
    Detailed description of the invention
    By introducing mutations into the polynucleotide and / or CpsA or CpsD protein sequence, the present inventors have surprisingly found that these bacteria produce higher amounts of capsular polysaccharide and that the capsular polysaccharide is secreted into the culture medium.
    The recombinant strains of Streptococcus agalactiae secrete an amount of capsular polysaccharide, in mg / l, determined by the methods described in the Examples, which is greater than that secreted by the wild-type strain cultured under the same culture conditions. In particular, these mutants show an increase in the level or amount of capsular polysaccharide secreted in the culture medium. In particular, the quantity or level is at least 10 percent, at least 20 percent, at least 30 percent, at least 40 percent, at least 50 percent, at least 60 percent at least 70 percent, at least 80 percent, at least 90 percent, at least 100 percent or more higher than that of a wild-type cell of the same serotype. More particularly, these mutants have a reduced amount of cell wall adherent capsular polysaccharide, in particular, an amount or level of 10 percent, 20 percent, 30 percent, 40 percent, 50 percent, 60 percent. percent, 70 percent, or 80 percent lower than that of a wild-type cell of the same serotype.
    In the context of the present invention, the term "capsular polysaccharide" is intended to designate the capsular polysaccharides of Streptococcus agalactiae. In GBS, one of the most important virulence factors is the capsular polysaccharide. To date, ten serotypes of the capsular polysaccharide have been discovered: Ia, Ib, II, III, IV, V, VI, VII, VIII and IX.
    Capsular saccharides
    The capsular saccharide of Streptococcus agalactiae is covalently bound to the peptidoglycan backbone of GBS, and is distinct from group B antigen, which is another saccharide bound to the peptidoglycan backbone. The capsular saccharides of GBS are chemically related, but are very different from the antigenic point of view. All capsular polysaccharides of GBS share the following trisaccharide core: B-D-GlcpNAc (1-3) β-D-Galp (1-4) β-D-Glcp
    The different serotypes of the GBS differ in the way this "core" is modified. The difference between serotypes la and III, for example, comes from the use of either GlcNAc (1a) or Gal (III) in this "core" to bind consecutive trisaccharide cores. Serotypes 1a and 1b both have a NeupNAc (2-> 3) βD Galp (1- →) disaccharide bound to GlcNAc in the "core", but the binding is either l-> 4 (la), GBS-associated diseases are mainly caused by serotypes Ia, Ib, II, III, IV, V, VI, VII, and VIII, more than 85% of which are caused by five serotypes: la, Ib, II, III & V. The invention preferably relates to a saccharide derived from one or more of these five serotypes, in particular from one or more of serotypes II and V. Capsular saccharides generally comprise: (a) an N-acetyl-neuraminic acid (NeuNAc) terminal residue (commonly referred to as "sialic acid"), which in all cases is 2-> 3-linked to a galactose residue, and (b) a N-acetyl-glucosamine residue (GlcNAc) in the trisaccharide core.
    When the saccharide of GBS has been purified by basic extraction, O-acetylation is typically lost. In particular, the capsular polysaccharides extracted by the processes according to the invention are entirely O-acetylated and / or N-acetylated and are not deacetylated (either partially or entirely). The effect of deacetylation etc. can be evaluated by routine dosages.
    In particular, the degree of oxidation of the sialic acid of the capsular polysaccharide of GBS is not less than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85% , 90%, 95% and in particular the content of N-acetyl-neuraminic acid (NeuNAc or sialic acid) of the capsular polysaccharide of GBS serotype V is greater than 50%, greater than 60%, greater than 70%, greater than 75%, greater than 80%, greater than 85%, greater than 90%, greater than 95%, compared to that of the native polysaccharide in which the content of NeuNAc is considered to be about 100%. In particular, the polysaccharide of GBS is a fully sialylated or "native" polysaccharide, for example, having a sialic acid content of about 100%, 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, about 90% (or any range between these values) compared to the native GBS polysaccharide.
    The purified saccharide according to the invention may be shorter or longer than the naturally occurring GBS polysaccharide or isolated from a wild-type bacterium. Longer polysaccharides can be depolymerized to obtain shorter fragments. ex. by hydrolysis in a mild acid, by heating, size exclusion chromatography, etc.
    ACSC
    An example of a full-length CpsA amino acid sequence comprises the sequence deposited under Uniprot accession number Q9RPC7 having the following amino acid sequence (SEQ ID NO: 2):
    MSNHSRRQQKKHSHTPLRVINLFLLVIFILLSWSLFLMYRHHFLAFRHLNVIYGWIV
    LIILASLFLCIKNKARIFTTIILVLASIFVATTLYGFKSTIDLTNNLNKTASYSEIEMSVIVP
    KDSKITNIEAVSKLAAPVKNDTSNITDLIEHIKSEKGISITPQKTDSYQDAYNRIKNGDS
    QAMVLNNAYVSLIELSTPDFKSQIKTIYTYKIKKKINRKNTNHKEGVFNIYISGIDTFGSI
    STVSRSDVNIIMTVNTNTHKVLLTTTPRDAYVKIPDGGGNQYDKLTHAGLYGVETSM
    KTLENLYDINLDYYARINFSSFLKLIDLLGGVTVYNDQAFTSKHGNFDFPVGQVTLNS
    EQALGFVRERYSLQGGDNDRGRNQEKVIAAIINKLASSQSVTKLNSITSQLQTSVQT
    NMTIDNINDLINNQLSTGQRFTVESQALTGHGSTGELPSYAMPGAQLYMMSIDQSSL SNAKSKIKNTMEE-
    In some embodiments, the present invention is based on the mutation of the CpsA gene by deletion in the reading frame or other mutations such as substitutions. A deletion in the CpsA gene reading frame may include any truncation of any part of the CpsA gene. Deletions in the reading frame according to the present invention include deletions that remove a segment of the protein coding sequence, while retaining the proper reading frame after the deletion. Certain embodiments according to the present invention may include deletions that are "clean deletions" ie, that do not contain exogenous DNA sequences inserted into the gene or a deletion in the CpsA gene reading frame may include a elimination at any position from 1 to 485 amino acids. The inventors have thus identified residues within SEQ ID NO: 2 that can be modified to alter the activity of CpsA so that the adhesion of the capsular polysaccharide to the cell wall is reduced while the secretion or release capsular polysaccharide in the external environment, for example, in the culture medium is increased. In addition, the mutation of these residues can be combined with other modifications such as deletions.
    The CpsA mutants comprise a mutation in the polynucleotide sequence (SEQ ID NO: 1) that encodes the polypeptide sequence of CpsA exposed in SEQ ID NO: 2, the mutation resulting in increased secretion of the capsular polysaccharide in the culture medium. In particular, the mutation is chosen from the group consisting of a deletion in the reading frame, a point mutation such as a substitution, a deletion, and an insertion.
    In some embodiments, the mutation results in the deletion of the polynucleotide sequence that encodes the entire CpsA polypeptide. In other embodiments, the mutation comprises a deletion wherein the protein corresponding to the deletion mutation is deprived of at least 2 amino acids. More particularly, the mutation comprises a deletion of a portion of the polynucleotide sequence that encodes the LytR and / or PFAM region of the CpsA polypeptide. The LytR domain may comprise amino acids 236 to 458 of SEQ ID NO: 2, in particular amino acids 248 to 395 of SEQ ID NO: 2, in particular the LytR domain may consist of SEQ ID NO: 40. The region or the PFAM domain of the CpsA polypeptide may comprise or consist of amino acids 72 to 187 of SEQ ID NO: 2, in particular the PFAM domain may comprise or consist of SEQ ID NO: 41. In some embodiments, the CpsA gene comprises a point mutation, in particular a point mutation of one or more of the following residues, numbered according to the CpsA protein of SEQ ID NO: 2, which causes the loss or reduction of CpsA activity and an increase in secretion of the capsular polysaccharide: D238, R248, D250, K263, R271, R366, R368, R271, D375, R378, Q382, T437 and E439. More particularly, the CpsA gene comprises one or more point mutations selected from the group consisting of D238, R248, R271 and R366 numbered according to the CpsA protein of SEQ ID NO: 2. Without wishing to be bound by a theory, the inventors believe that these residues, which are generally conserved, may be relevant for substrate binding and / or substrate recognition.
    The capsular polysaccharides produced by wild type Streptococcus agalactiae have a molecular weight of about 367 kDa. The capsular polysaccharides secreted by the CpsA mutants described herein have a molecular weight greater than 800 kDa.
    Therefore, the invention also relates to a purified capsular polysaccharide having a molecular weight, in particular an average molecular weight greater than 800 kDa, greater than 900 kDa, greater than 1000 kDa, greater than 1100 kDa, greater than 1200 kDa, greater at 1300 kDa, greater than 1400 kDa, greater than 1500 kDa, greater than 1600 kDa, about 1700 kDa, particularly about 1758 kDa, or any intermediate range. Analysis of the CpsA mutants revealed that a portion of the capsular polysaccharide adheres to the bacterial cell wall, namely, that it is not fully secreted. Analysis of this capsular polysaccharide indicates that it has a molecular weight of about 210 kDa. Therefore, in some embodiments, the capsular polysaccharide can be extracted from the cell wall of CpsA mutants using the prior art methods to obtain a capsular polysaccharide having a molecular weight of less than 300 kDa. less than 250 kDa, in particular about 210 kDa.
    CPSD
    An example of a full-length CpsD amino acid sequence comprises the sequence deposited under Uniprot accession number K0JNC2 having the following amino acid sequence (SEQ ID NO: 11):
    MTRLEIVDSKLRQAKKTEEYFNAIRTNIQFSGKENKILAITSVREGEGKSTTSTSLALS
    LAQAGFKTLLIDADTRNSVMSGTFKATGTIKGLTNYLSGNADLGDIICETNVPRLMW
    PSGKVPPNPTALLQNAYFNKMIEAIKNIFDYIIIDTPPIGLWDAAIISNACDGFILVTQA
    GRIKRNYVEKAKEQMEQSGSKFLGIILNKVSESVATYGDYGDYGNYGKRDRKRK
    In some embodiments, the present invention is based on the deletion of the CpsD gene in the reading frame or other mutations such as substitutions. A deletion in the CpsD gene reading frame may include any truncation of any part of the CpsD gene. Deletions in the reading frame according to the present invention include deletions that remove a segment of the protein coding sequence, while retaining the proper reading frame after the deletion. Certain embodiments according to the present invention may include deletions that are "clean deletions" ie, that do not contain exogenous DNA sequences inserted into the gene or deletion in the reading frame of the CpsD gene may include a elimination at any position from 1 to 232 amino acids. The inventors have thus identified residues within SEQ ID NO: 10 that can be modified to alter the CpsD activity so that adhesion of the capsular polysaccharide to the cell wall is reduced while secretion or release. capsular polysaccharide in the external environment, for example, in the culture medium is increased. In addition, the mutation of these residues can be combined with other modifications such as deletions.
    The CpsD mutants comprise a mutation in the polynucleotide sequence (SEQ ID NO: 10) that encodes the CpsD polypeptide sequence set forth in SEQ ID NO: 11, the mutation resulting in increased secretion of the capsular polysaccharide into the culture medium. In particular, the mutation is chosen from the group consisting of a deletion in the reading frame, a point mutation such as a substitution, a deletion, and an insertion.
    In some embodiments, the mutation results in the deletion of the polynucleotide sequence that encodes the entire CpsD polypeptide. In other embodiments, the mutation comprises a deletion wherein the protein corresponding to the deletion mutation is deprived of at least 2 amino acids. More particularly, the mutation comprises a deletion of the portion of the polynucleotide sequence that encodes the phosphoacceptor site (P-tyr region) of the CpsD polypeptide. Other mutations include a deletion of a region from C-terminal Tyr to Phe. In some embodiments, the CpsD gene comprises one or more point mutations selected from the group consisting of K49, S50, D73 and P154, for example, by way of non-limiting example, K49M and / or S50A. In particular, mutations in the active site of autokinase, in particular a point mutation at position K49 numbered according to the CpsD protein of SEQ ID NO: 11 which causes the loss or reduction of CpsD activity and an increase in secretion of the capsular polysaccharide are useful.
    The capsular polysaccharides produced by wild type Streptococcus agalactiae have a molecular weight of about 367 kDa. The capsular polysaccharides secreted by the CpsD mutants described herein have a molecular weight greater than 800 kDa.
    Therefore, the invention may also relate to a purified capsular polysaccharide having a molecular weight, in particular an average molecular weight greater than 800 kDa, greater than 900 kDa, greater than 1000 kDa, greater than 2000 kDa, greater than 3000 kDa, greater than 4000 kDa, greater than 5000 kDa, greater than 6000 kDa, greater than 7000 kDa, greater than 8000 kDa, greater than 9000 kDa or any intermediate range.
    variants
    Variants of CpsA and CpsD from other strains of Streptococcus agalactiae are known and can be easily identified, for example, using BLAST programs to search for the above sequence. The variants of CpsA include, by way of nonlimiting examples, the strains deposited under Uniprot accession numbers: M1Y5W8, S9KSV2, S9JM66 and S8YXF5, also designated "transcriptional regulator of the LytR family", "CpsX regulatory protein", "Capsular polysaccharide biosynthesis protein CpsX" and others. The CpsD variants include, by way of nonlimiting examples, the strains deposited under Uniprot accession numbers: V6H970, S9NRN3, S9PP30, S9E9Q3, also designated "tyrosine protein kinase" and "capsular polysaccharide transporter" and others. .
    Therefore, the invention also applies to allelic variants of CpsA and CpsD proteins derived from
    Streptococcus agalactiae described. In some embodiments, the degree of sequence identity is greater than 80%, 90%, 95%, 96%, 97%, 97.5%, 98%, 98.5%, 99%, 99.5%. % or more. These polypeptides include homologs, orthologs, allelic variants, and functional mutants. Generally, an identity of 50% or more between two polypeptides is considered to indicate functional equivalence.
    Purification
    Starting material: CpsA and CpsD mutants secrete and release large amounts of capsular polysaccharide in the culture medium during bacterial growth, so that the starting material for purification is usually the supernatant of a centrifuged bacterial culture. Through the use of CpsA or CpsD mutants, it is not necessary to treat the capsulated bacteria themselves to release the capsular saccharide. Advantageously, since the process according to the invention does not require the use of basic reagents such as NaOH, the saccharide produced by the processes according to the invention is not partially or completely de-N-acetylated and the processes according to the invention do not comprise or require an N-re-acetylation step.
    Precipitation by addition of an alcohol and cation exchange: The capsular saccharide of GBS obtained after cultivation will generally be impure and may be contaminated by nucleic acids and proteins of bacterial origin. The process according to the invention uses precipitation by addition of alcohol. Since the basic extraction is not used, the materials will not need to be neutralized before precipitation, which again reduces the time required to purify the capsular polysaccharide. The alcohol used to precipitate the contaminating nucleic acids and / or proteins is preferably a lower alcohol, such as methanol, ethanol, propan-1-ol, propan-2-ol butan-1-ol, butan-2-ol, 2-methyl-propan-1-ol, 2-methyl-propan-2-ol, diols, etc. The choice of the appropriate alcohol can be tested empirically, without unduly burdening the process, but alcohols such as ethanol and isopropanol (2-propanol) are preferred, rather than alcohols such as phenol. The alcohol is preferably added to the polysaccharide suspension so as to obtain a final alcohol concentration of between 10 and 50% (e.g., about 30%). The most useful concentrations are those that induce adequate precipitation of the contaminants without precipitating the polysaccharide at the same time. The optimal final alcohol concentration may depend on the serotype of the GBS from which the polysaccharide is obtained, and may be determined by conventional experiments without excessive work overload. Precipitation of the polysaccharides at ethanol concentrations> 50% was observed. The alcohol can be added in pure form or in a diluted form with a miscible solvent (eg water). Preferred solvent mixtures are ethanol / water mixtures, at a preferred ratio of about 70/30 to about 95/5 (eg, 75/25, 80/20, 85/15, 90/10).
    The saccharide is also treated with an aqueous metal cation. Monovalent and divalent metal cations are preferred, and divalent cations such as Mg ++, Mn ++, Ca ++, etc., are particularly preferred because they are more effective at forming complexes. The calcium ions are particularly useful, and therefore the alcohol addition mixture preferably contains soluble calcium ions which can be added to a saccharide / alcohol mixture as calcium salts, either in solid form or in the form of calcium. aqueous. Calcium ions are preferably provided by calcium chloride.
    The calcium ions are preferably present at a final concentration between 10 and 500 mM p. ex. about 0.1 M. The optimal final Ca ++ concentration may depend on the GBS serotype from which the polysaccharide is obtained, and may be determined by conventional experiments without excessive work overload. Alcohol and cation play different roles (the alcohol serves to precipitate the contaminants, while the cation stabilizes and forms a complex with the saccharide in soluble form) but produces a combined effect. Although the purpose is to prepare a mixture of saccharide, alcohol and cation, these three components do not necessarily need to be mixed simultaneously. The alcohol and the cation can thus be used sequentially or simultaneously. Sequential processing is preferred, and a particularly preferred method involves adding the cation to the saccharide followed by adding the alcohol to the cation / saccharide mixture, although the alcohol can be used before the cation if desired.
    After precipitation of the contaminating proteins and / or nucleic acids by addition of alcohol, the capsular polysaccharide of the GBS is left in solution. The precipitated material may be separated from the polysaccharide by any suitable means, such as by centrifugation. The supernatant can be subjected to microfiltration, and in particular to a frontal filtration (perpendicular filtration) in order to eliminate the particles liable to seal the filters in the subsequent steps (for example particles having precipitated with a diameter greater than 0 , 22 micrometer). In place of frontal filtration, tangential microfiltration can be used.
    Diafiltration: The method according to the invention may include a diafiltration step after the precipitation of proteins and / or nucleic acids. Tangential flow diafiltration can be used. The filtration membrane must therefore be of the type which allows the impurities to pass while retaining the capsular polysaccharide. A cut in the range of 10 to 30 kDa is typical. The low cut-off thresholds may be used but the high-limit cut-offs advantageously permit the removal of other contaminants without causing the loss of the capsular saccharide. At least 1 diafiltration cycle can be implemented, eg ex. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or more.
    In some embodiments, the method further comprises a step of removing nucleic acids and / or contaminating proteins. Particularly contaminating nucleic acids and / or proteins can be removed by precipitation. More particularly, the contaminating nucleic acids and / or proteins can be separated from the capsular polysaccharide in aqueous form by precipitation by addition of alcohol. When an alcohol addition precipitation step is included, an alcohol and an aqueous metal cation can be used to precipitate the nucleic acids and / or proteins, leaving the polysaccharide in solution. When an alcohol addition precipitation step is included, the method may include an additional step of separating the material having precipitated polysaccharide. In particular, the precipitated material can be separated from the polysaccharide by filtration and more particularly, the process can comprise a diafiltration step after the precipitation of the nucleic acids and / or proteins. In some embodiments, the alcohol is ethanol or isopropanol. In some embodiments, the aqueous metal cation is CaCl 2. In particular, the methods according to the invention will comprise one or more filtration steps, for example ultrafiltration and / or gel filtration. In particular embodiments, a gel filtration of Sephacryl® is carried out, for example, on Sephacryl® S-500 gel.
    Additional Treatment of Capsular Polysaccharide: The polysaccharide can be further processed to remove contaminants. This is particularly important in cases where even minor contamination is unacceptable (eg for the production of vaccines for human use). For example, other precipitation steps may be used. When an aqueous solubilization has been performed, then this precipitation will typically use an alcohol, as described in the previous section; conversely, when alcohol addition resolubilization has been performed, then this precipitation will typically use an aqueous cationic solution, as described in the previous section. The precipitated saccharide can then be separated from any residual aqueous contaminants p. ex. by centrifugation. The precipitated material is stable and can be stored for later use. Additional precipitation and filtration towers can also be implemented. Deep filtration may also be used, eg ex. instead of centrifugation. Depth filtration will typically be used after solubilization in an alcohol.
    The precipitated material can be vacuum dried. This treatment will typically be used not to stabilize the saccharide for storage purposes, but to dry and remove any residual alcohol. The method provides a capsular polysaccharide of purified Streptococcus agalactiae. In particular, the capsular polysaccharide is a sialylated capsular polysaccharide, in other words, it is neither partially nor completely de-N-acetylated. More particularly, about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% to about 100% of the repeating units of the purified capsular polysaccharide include completed side chains. by N-acetylneuraminic acid (sialic acid; Neu5Ac) a2,3-linked to galactose (Gai).
    The purified capsular polysaccharide according to the invention can be used as an antigen without any other modification p. ex. it can be used in in vitro diagnostic assays, for immunization, etc. For immunization purposes, however, it is preferable to conjugate the saccharide to a carrier molecule, such as a protein. In general, the covalent conjugation of saccharides to carrier proteins enhances the immunogenicity of the saccharides by passing them from T-dependent antigens to T-dependent antigens, thereby enabling the priming of an immunological memory. Conjugation is a very well known technique. Therefore, the methods of the invention may include the additional step of conjugating the purified saccharide to a carrier molecule. The invention may also relate to processes for the preparation of pharmaceutical compositions, comprising the steps of mixing (a) a polysaccharide according to the invention (optionally in the form of a conjugate) with (b) a pharmaceutically acceptable vehicle. The typical "pharmaceutically acceptable carrier" includes any vehicle that does not induce the production of harmful antibodies for the individual receiving the composition. Suitable vehicles are typically large, slowly metabolizing macromolecules, such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lactose, and lipid aggregates (such as as oil droplets or liposomes). These vehicles are well known to those skilled in the art. Vaccines may also contain diluents, such as water, saline, glycerol, etc. In addition, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present. Sterile phosphate-buffered saline, pyrogen-free, is a typical vehicle. The pharmaceutical compositions may be packaged in vials or in syringes. Syringes can be supplied with or without needles. A syringe will comprise a single dose of the composition, while a vial may contain a single dose or multiple doses. The aqueous saccharide compositions according to the invention are suitable for reconstituting other vaccines from a freeze-dried form. When a composition according to the invention is to be used for this type of extemporaneous reconstitution, the invention proposes a method of reconstituting this type of freeze-dried vaccine, comprising the step of mixing the lyophilized material with an aqueous composition according to the invention. The reconstituted material can be used for injection. Overview
    The term "including" includes "including" and "constituted by", p. ex. a composition "comprising" X may consist exclusively of X or may include an additional element p. ex. X + Y. The term "essentially constituted by" means that the composition, process or structure may comprise additional ingredients, steps and / or parts, but only if the ingredients, steps and / or additional parts do not materially alter the basic and novel characteristics of the claimed composition, process or structure. By "constituted by" is generally meant that the invention as claimed is limited to the elements specifically identified in the claim (and may include their equivalents, if the doctrine of equivalents applies).
    The term "about" as used herein with reference to a measurable value such as quantity, time duration, and the like, is intended to encompass variations of ± 20% or ± 10%, more preferably of ± 5%, more preferably ± 1%, and more preferably ± 0.1% of the specified value, to the extent that these variations are appropriate for the implementation of the methods described.
    The term "essentially" does not exclude "completely" p. ex. a composition which is "substantially free" of Y may be completely free of Y. For example, "substantially free" of Y may be understood as a composition containing not more than 5% Y, not more than 4% Y, not more than 3% of Y, not more than 2% of Y, not more than 1% of Y, or not more than 0.1% of Y. If necessary, the term "substantially" may be omitted from the definition of 1'invention.
    Unless otherwise indicated by context, the term "or" as used herein is inclusive and may be used interchangeably with the term "and / or".
    The term "mutant" refers to a gene or gene product that exhibits changes in its sequence and / or functional properties (i.e., altered characteristics) relative to the gene or gene product of the wild type.
    All GenBank Access Numbers mentioned herein are incorporated by reference into the version available on the filing date of this application.
    The term "recovery" refers to the isolation of the capsular polysaccharide at different degrees of purity, for example purity between 5 and 100%, with preferred purities ranging from 10 to 99%, from 20 to 99%, from 30 to 100%. 99%, 40 to 99%, 50 to 99%, 60 to 99%, 70 to 99%, 80 to 99%, 90 to 99%. The particular purities are greater than 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99%. Recovery may also be referred to as extraction or purification. The term "purity" has the general meaning used in the state of the art to refer to the percentage of the available, isolated sample actually representing the capsular polysaccharide.
    This invention is further illustrated by the following examples which should not be construed as limiting.
    EXAMPLES
    Bacterial strains and growth conditions GBS 515 (Wessels, et al., 1993) and its isogenic derivatives were grown in Todd-Hewitt broth (THB medium, Difco Laboratories) at 37 ° C, 5% CO 2. Tryptic soy broth (Difco Laboratories), 15 g / L agar (TSA) was used as a solid medium. Strains were stored at -80 ° C in THB + 15% glycerol. MAX Efficiency® DH5a ™ competent cells (Invitrogen) and E. coli HK100 cells. Internally prepared, competent E. coli were used for plasmid transformation, propagation, and preparation. E. coli was cultured at 37 ° C with shaking (180 rpm) in Luria-Bertani broth (LB, Difco laboratories), or on 15 g / L agar plates (LBA). Erythromycin (Erm) was used for the selection of GBS (1 μg / ml) or E. coli (100 μg / ml) containing plasmids derived from pJRS233 (Perez-Casal et al., 1993) used for mutagenesis. . Kanamycin (Kan) was used for the selection of E. coli (50 μg / ml) containing the plasmids derived from pET24b (Novagen) used for the initial mutagenesis of the inserts, before transfer into pJRS233.
    Construction of CpsA Plasmids for Mutagenesis and Chromosome Complementation
    To prepare each mutant strain, the shuttle vector pJRS233 (Perez-Casal J, et al., 1993) containing the gene locus carrying a deletion in the reading frame or a codon substitution was constructed. The mutant strains developed are described in Table 1:
    The primers used are shown in Table 2 below:
    Constructs for genes carrying codon substitutions were prepared using splicing by the extension-overlap PCR (SOEing-PCR) strategy. Briefly, both portions of the gene downstream and upstream of the codon substitution were amplified from strain 515 gDNA using PfuUltra II Fusion HS DNA polymerase (Agilent Technologies). 900-1000 bp upstream and downstream of the coding sequence of the gene were added to the inserts. The primers used to amplify both parts of the gene have 15 bp overlapping tails and introduce the codon substitution into the two PCR products that are then assembled by SOEing-PCR. The resulting fragment was ligated into pJRS233 using BamHI and XhoI restriction sites.
    Constructs for genes carrying deletions in the reading frame were prepared by the polymerase incomplete primer extension (PIPE) method. Briefly, the plus 900-1000 bp gene upstream and downstream of the coding sequence was amplified from the gDNA of strain 515 and cloned into pET24b using the NotI and XhoI restriction sites (cpsA inserts) or BamHI. and Xhol (cpsD inserts). Deletions in the gene reading frame were developed by amplification of the plasmid using primers with overlapping 15 bp tails hybridizing to both sides of the deleting region. The linear plasmids were transformed into competent HK100 cells capable of re-circularizing the plasmid. The inserts obtained were then transferred into the plasmid pJRS233 by restriction digestion and ligation.
    The constructs for chromosomal complementation were prepared by transferring into pJRS233 wild type inserts cloned into pET24b.
    Construction of CpsD Plasmids for Mutagenesis and Chromosome Complementation
    To prepare each mutant strain, the shuttle vector pJRS233 (Perez-Casal J, et al., 1993) containing the gene locus carrying a deletion in the reading frame or a codon substitution was constructed. The mutant strains developed are described in Table 3:
    The primers used are indicated in Table 2 below:
    Constructs for genes carrying codon substitutions were prepared using splicing by the extension-overlap PCR (SOEing-PCR) strategy. Briefly, both portions of the gene downstream and upstream of the codon substitution were amplified from strain 515 gDNA using PfuUltra II Fusion HS DNA polymerase (Agilent Technologies). 900-1000 bp upstream and downstream of the coding sequence of the gene were added to the inserts. The primers used to amplify both parts of the genes have 15 bp overlapping tails and introduce the codon substitution into the two PCR products which are then assembled by SOEing-PCR. The resulting fragment was ligated into pJRS233 using BamHI and XhoI restriction sites.
    Constructs for genes carrying deletions in the reading frame were prepared by the polymerase incomplete primer extension (PIPE) method. Briefly, the plus 900-1000 bp gene upstream and downstream of the coding sequence was amplified from the 515 strain's DNA and cloned into pET24b using the NotI and XhoI restriction sites (cpsA inserts) or BamHI. and Xhol (cpsD inserts). Deletions in the gene reading frame were developed by amplification of the plasmid using primers with overlapping 15 bp tails hybridizing to both sides of the deleting region. The linear plasmids were transformed into competent HK100 cells capable of re-circularizing the plasmid. The inserts obtained were then transferred into the plasmid pJRS233 by restriction digestion and ligation.
    The constructs for chromosomal complementation were prepared by transferring into pJRS233 wild type inserts cloned into pET24b.
    Construction of Isogenic Mutants and Chromosomally Complemented Strains
    An insertion / duplication and excision mutagenesis strategy was used both to obtain the deletion in the codon reading / substitution frame in the genes and to replace the mutations to obtain the chromosomally complemented strains. Briefly, plasmids derived from pJRS233 purified from E. coli were used to transform electrocompetent cells of strain 515 by electroporation. Transformants were selected by growth on TSA + Erm at 30 ° C for 48 hours. The integration was carried out by growth of the transformants at 37 ° C. (temperature not permissive for the suicide shuttle vector) with selection by Erm. Excision of the integrated plasmid was performed by serial passages in THB at 30 ° C, and parallel screening for plaque-sensitive Erm colonies. The mutants were verified by sequencing the loci by PCR.
    To get . chromosomally complemented strains, plasmids derived from pJRS233 containing the wild-type gene form and 900-1000 bp flanking upstream and downstream were purified from E. coli and complementation of the respective mutant strains was carried out as described for mutagenesis.
    QRT-PCR analysis
    Bacteria were harvested at two time points: ODeoo = 0.4 (log phase) and OD50o = 1.7 (early stationary phase). To rapidly stop transcription, 10 ml of bacteria were chilled on ice and added to 10 ml of frozen THB medium in a 50 ml conical tube. The GBS cells were then collected by centrifugation for 15 minutes at 4000 rpm, 4 ° C., and resuspended in 800 μl of TRIzol (Invitrogen). The bacteria were mechanically broken by stirring in lysis matrix B in 2 ml tubes (DBA Italy) using a homogenizer (Fastprep-24, Millipore) for 60 sec at 6.5 m / sec for two cycles, and kept on ice for 2 min between cycles. The samples were then centrifuged for 5 min at 8000 x g, 4 ° C and the RNA was extracted using the Direct-zol ™ RNA MiniPrep Kit (Zymo
    Research) according to the manufacturer's instructions. The RNA samples were treated with DNase (Roche) for 2 h at 37 ° C and then purified using the MiniPrep RNA kit (Qiagen), containing a second column DNase treatment for 30 min at room temperature. (TA) according to the manufacturer's instructions. The cDNA was prepared using the Reverse Transcription System (Promega) using 500 ng RNA per reaction. Real time quantitative PCR (qRT-PCR) was performed on 50 ng of cDNA which was amplified using LightCycler® 480 SYBR Green I Master DNA, (Roche). Reactions were monitored using the LightCycler® 480 and its software (Roche). Three technical replicates were monitored for each strain / condition analyzed. To quantify the level of transcription of cps operons, primers hybridizing to cpsA and cpsE were used for the cpsA mutants, respectively. The amounts of transcript in each condition were normalized to an internal control gene (gyrA) and compared to normalized expression in the wild-type strain (ΔΔΟτ method).
    Quantification of the capsular polysaccharide adhering to the cell surface
    Overnight culture was used to inoculate (1: 1000) 50 ml of fresh THB and the bacteria were cultured at 37 ° C for 8 hours. The GBS cells were collected by centrifugation for 15 min at 4000 rpm at 4 ° C, resuspended in 1.1 ml of PBS + 0.8 M NaOH and incubated at 37 ° C for 36 hours. The samples were neutralized and pellets were obtained by centrifugation for 10 min at 4000 rpm, 4 ° C. 850 μl of the supernatant was diluted in 7.15 ml of water, and centrifuged for 10 min at 4000 rpm at 4 ° C. 7.2 μl of the supernatant was loaded onto a Vivaspin tube (Sartorius Stedim Biotech) which was centrifuged at 4000 rpm until most of the solution passed through the membrane. After two washes with 1 ml of water, the CPS extract was recovered from the membrane and resuspended in 1.6 ml of water. The amount of CPS present in the extract was estimated by measuring the sialic acid content using the resorcinol-hydrochloric acid colorimetric method (Svennerholm et al., 1957). Briefly, 120 μl of extract were mixed with 380 μl of water and 500 μl of freshly prepared R3 solution (0.2% resorcinol, 0.3 mM copper sulfate, 30% HCl in H2O). The samples were boiled for 20 minutes, then cooled to room temperature before being transferred to 1 ml cuvettes to measure their absorbance at 564 nm. The sialic acid content of the samples was then calculated using a standard curve prepared concomitantly using serial dilutions of purified sialic acid. CPS extracts were prepared three times from independent cultures to minimize biological variability.
    Quantification of capsular polysaccharide released into the growth medium
    Overnight culture was used to inoculate (1: 1000) 10 ml of fresh THB and the bacteria were cultured at 37 ° C for 8 hours. GBS cell pellets were obtained by centrifugation for 15 min at 4000 rpm at 4 ° C, and the growth medium was collected and filtered using a 0.22 μm Nalgene syringe filter disc. (Thermo Scientific). The amount of capsular polysaccharide released into the growth medium was estimated by membrane transfer by the dot blot technique. 10 mg / ml purified serotype CPS were used as standard. Eight serial dilutions were prepared in a 96-well plate by dilution of the standard and growth medium in PBS (1: 2 dilution rate for medium, 1: 4 for standard). 2 μΐ of each serial dilution was transferred to a nitrocellulose membrane. The membrane was dried for 20 min and blocked by immersion in 5% (w / v) skim milk in 0.05% PBS-Tween. The membrane was then tested with an anti-CPS serotype Ia-CRM conjugate mouse monoclonal antibody (30E9 / B11) used at 1: 2000, washed 3 times in PBS-Tween 0.05%, and incubated. in 1: 15000 horseradish peroxidase conjugated goat anti-mouse antibody. Detection was performed using a Thermo Scientific Pierce ECL Western Transfer Substrate according to the manufacturer's instructions.
    Western blot transfer of the capsular polysaccharide released in the growth medium 20 μl of the medium were mixed with 10 μl of 3x NuPAGE® LDS sample buffer + reducing agent and boiled for 5 min. Then, 20 μΐ were loaded onto a NuPage 4-12% Bis-Tris gel, 1.0-well, 12-well (Life Technologies) (Buffer: MOPS 1x) and subjected to 150 V until the band corresponding to 28 kDa of the SeeBlue® Plus2 Prestained Protein Standard (Life Technologies) reached the bottom of the gel. Separate samples on the gel were transferred to a nitrocellulose membrane using the iBlot® 7-Minute Blotting System (Life Technologies) transfer system. The membrane was blocked by immersion in 5% (w / v) skim milk in 0.05% PBS-Tween. The membrane was then tested with an anti-CPS serotype Ia-CRM conjugate mouse monoclonal antibody (30E9 / B11) used at 1: 2000, washed 3 times in PBS-Tween 0.05%, and incubated. in 1: 15000 horseradish peroxidase conjugated goat anti-mouse antibody. Detection was performed using a Thermo Scientific Pierce ECL Western Transfer Substrate according to the manufacturer's instructions.
    Purification of the capsular saccharide from the culture medium
    The supernatant from the culture medium was collected by centrifugation after culturing CpsA mutants of Streptococcus Group B. A mixture of aqueous ethanol (30%) and CaCl 2 (0.1M) was added to the culture medium. A precipitate formed rapidly, which was separated by centrifugation. Sialic acid assays showed that the capsular saccharide remained in the supernatant. The supernatant was subjected to frontal microfiltration on regenerated cellulose filters (cut at 0.22 μιη). The supernatant was then subjected to tangential flow filtration (TFF) using a 30 kDa cut-off cellulose membrane against 50 mM Tris / 500 mM NaCl pH 8.8 and then to diafiltration against 10 mM NaPi, pH 7.2 . Again, the precipitate was separated by centrifugation. An additional step of Sephacryl S-500 resin gel filtration was used. The polysaccharide can be recovered as a pool of fractions, which in some cases are dried, for example, by vacuum drying. Those skilled in the art will recognize, or will be able to determine by simple routine experiments, many equivalents to the specific embodiments of the invention described herein. These equivalents are intended to be encompassed by the following claims.
    REFERENCES
    Wessels, M.R., Paoletti, L.C., Rodewald, A.K., Michon, F., DiFabio, J., Jennings, H.J. & Kasper, D. L. (1993) Infect. Immun. 61, 4760-4766.
    Perez-Casal J, Price JA, Maguin E, Scott JR. (1993) Mol Microbiol 8, 809-819.
    Svennerholm L., (1957) Biochim Biophys Acta. 24 (3), 604-611.
    INDEX OF SEQUENCE ID
    SEQ ID NO: 1 - CpsA DNA sequence
    SEQ ID NO: 2 - Amino acid sequence CpsA SEQ ID NO: 3 - Amino acid sequence CpsA LytR (aa 236-458)
    SEQ ID NO: 4 - ALytR CpsA Polynucleotide Sequence
    SEQ ID NO: 5 - ALytR CpsA amino acid sequence
    SEQ ID NO: 6 - AcpsA nucleotide sequence
    SEQ ID NO: 7 - Amino acid sequence AcpsA SEQ ID NO: 8 - CpsA nucleotide sequence (Aext_domain) SEQ ID NO: 9 - Amino acid sequence CpsA (Aext_domain)
    SEQ ID NO: 10 - Wild type cpsD nucleotide sequence SEQ ID NO: 11 - Wild type cpsD amino acid sequence SEQ ID NO: 12 - AcpsD nucleotide sequence
    SEQ ID NO: 13 - AcpsD amino acid sequence SEQ ID NO: 14 - CpsD nucleotide sequence (K49A) SEQ ID NO: 15 - CpsD amino acid sequence (K49A) SEQ ID NO: 16 - CpsD nucleotide sequence (AP -Tyr) SEQ ID NO: 17 - CpsD amino acid sequence (AP-Tyr) SEQ ID NO: 18 - NotA5Fsoe primer SEQ ID NO: 19 - XhA3Rsoe primer SEQ ID NO: 20 - KOA5Rsoe primer SEQ ID NO: 21 - Primer KOA3Fsoe SEQ ID NO: 22 - Primer MlA5Rsoe SEQ ID NO: 23 - Primer MlA3Fsoe SEQ ID NO: 24 - Primer M2A5Rsoe SEQ ID NO: 25 - Primer M2A3Fsoe SEQ ID NO: 26 - Primer BaD5Fsoe SEQ ID NO: 27 - Primer XhD3Rsoe SEQ ID NO: 28 - KOD5Rsoe primer SEQ ID NO: 29 - KOD3Fsoe primer
    SEQ ID NO: 30 - MlDmutF primer
    SEQ ID NO: 31 - MlDmutR primer SEQ ID NO: 32 - M2D5Rsoe primer SEQ ID NO: 33 - M2D3Fsoe primer
    SEQ ID NO: 34 - Boot SAN_1047F
    SEQ ID NO: 35 - Boot SAN_1047R
    SEQ ID NO: 36 - Primer SAK_1262F
    SEQ ID NO: 37 - SAK_1262R Primer
    SEQ ID NO: 38 - Primer SAK_1258F
    SEQ ID NO: 39 - Primer SAK_1258R SEQ ID NO: 40 - CpsA Domain LytR aa 248-395 SEQ ID NO: 41 - CPSA Domain PPF / PFAM aa 72-187
    权利要求:
    Claims (15)
    [1]
    A method of producing a capsular polysaccharide from Streptococcus agalactiae comprising: culturing in a suitable culture medium a CpsA or CpsD mutant which exhibits increased secretion of the capsular polysaccharide compared to the wild-type strain and recovery polysaccharide from the culture medium.
    [2]
    The method of claim 1 wherein the CpsA mutant comprises: (a) an altered CpsA protein in which the nucleotide sequence encoding an amino acid sequence comprising the CpsA protein (SEQ ID NO: 2) is deleted or partially deleted; or (b) an altered CpsA protein in which the nucleotide sequence that encodes for (i) the LytR domain of SEQ ID NO: 40 or SEQ ID NO: 3 and / or (ii) the PFAM domain of SEQ ID NO: 41 is deleted; or (c) an altered CpsA protein, the altered CpsA protein substituted with at least one amino acid residue selected from the group consisting of: R271, R366, D375, R378 and Q382 numbered according to the CpsA protein (SEQ ID NO: 2); and / or (d) an altered CpsA protein, the altered CpsA protein substituted with at least one amino acid residue selected from the group consisting of: D238, R248, D250, R271 and R368 numbered according to the CpsA protein (SEQ ID NO: 2); and wherein the CpsA mutant has increased secretion of the capsular polysaccharide compared to the wild-type strain.
    [3]
    The method of claim 1 wherein the CpsD mutant comprises: (a) an altered CpsD protein wherein the nucleotide sequence encoding a mined acid sequence comprising SEQ ID NO: 13 in wild-type Streptococcus agalactiae is deleted; or (b) an altered CpsD protein, the altered CpsD protein substituted with at least one amino acid residue selected from the group consisting of K49, S50, D73 and P154 numbered according to SEQ ID NO: 11; or (c) an altered CpsD protein encoded by the nucleic acid sequence SEQ ID NO: 16; wherein the CpsD mutant has increased secretion of the capsular polysaccharide compared to the wild-type strain.
    [4]
    The method of claim 1, 2 or 3, wherein the mutant has an increase in secreted polysaccharide level that is at least 10 percent, at least 20 percent, at least 30 percent, at least 40 per cent, at least 50 per cent, not less than 60 per cent, not less than 70 per cent, not less than 80 per cent, not less than 90 per cent, not less than 100 per cent or more of a wild-type cell of the same serotype.
    [5]
    A method according to any one of the preceding claims, wherein the polysaccharide is derived from a serotype of Streptococcus agalactiae selected from the group consisting of Ia, Ib, II, III, IV, V, VI, VII or VIII, in particular serotypes la, Ib, II, III or V.
    [6]
    The process of any of the preceding claims, wherein the polysaccharide has a molecular weight greater than 800 kDa.
    [7]
    7. A process according to any one of the preceding claims, wherein the saccharide is neither partially nor completely de-N-acetylated.
    [8]
    The method of any of the preceding claims, further comprising the step of removing nucleic acids and / or contaminating proteins by precipitation.
    [9]
    The method of claim 8, wherein the method comprises the steps of: (a) removing nucleic acids and / or contaminating proteins from the capsular polysaccharide in aqueous form by precipitation by adding an alcohol, in wherein an alcohol and an aqueous metal cation are used to precipitate nucleic acids and / or proteins and leave the polysaccharide in solution; and (b) separating the precipitated material from the polysaccharide.
    [10]
    The method of claim 8 or 9, wherein the method further comprises a diafiltration step after precipitation of the nucleic acids and / or proteins.
    [11]
    11. The process of claim 9 or 10, wherein the alcohol is ethanol or isopropanol.
    [12]
    The method of claim 11, wherein the aqueous metal cation is CaCl 2.
    [13]
    The method of any one of claims 8 to 12, further comprising one or more filtration steps.
    [14]
    14. Purified capsular polysaccharide of Streptococcus agalactiae obtained by the method according to any one of the preceding claims.
    [15]
    15. An immunogenic composition, in particular a vaccine composition, comprising the capsular polysaccharide according to claim 14.
    类似技术:
    公开号 | 公开日 | 专利标题
    Balachandran et al.2002|Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae
    KR102049826B1|2019-12-03|Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
    KR20160098507A|2016-08-18|Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
    BE1022878B1|2016-09-30|ANTI-MENINGOCOCCAL VACCINES
    KR20170039709A|2017-04-11|Carrier molecule for antigens
    BE1022641B1|2016-06-23|MENINGOCOCCAL POLYPEPTIDES fHbp MODIFIED
    Li et al.2012|Abrogation of neuraminidase reduces biofilm formation, capsule biosynthesis, and virulence of Porphyromonas gingivalis
    BE1022780B1|2016-09-02|PURIFICATION OF SECRET POLYSACCHARIDES BY S. AGALACTIAE
    EP0791063B1|2005-01-26|Carrier protein having an adjuvant effect, immunogenic complex containing same, preparation method therefor, nucleotide sequence and vaccine
    BE1025210B1|2018-12-12|IMMUNOGENIC CONJUGATES AND THEIR USE
    EP3544637B1|2020-11-11|Native omv-antigen conjugates and use thereof
    BE1024282B1|2018-01-15|IMMUNOGENIC COMPOSITIONS
    EP0914152A1|1999-05-12|Immunogenic complex, use, method of preparation thereof and vaccine containing same
    JP2022513562A|2022-02-09|Purified capsular polysaccharide of Streptococcus pneumoniae
    FR2736064A1|1997-01-03|New immunogenic fragments of Bordetella adenyl:cyclase haemolysin
    BE1024794B1|2018-07-10|IMMUNOGENIC COMPOSITIONS
    EP2942396A1|2015-11-11|Polysaccharides produced by CPSC mutants
    BE1022553B1|2016-05-31|MUTANTS OF SPY0269
    KR20210146392A|2021-12-03|Optimized cell-free synthesis of invasive plasmid antigen B and related compositions and methods of use
    JP2022514704A|2022-02-14|O-linked glycosylation recognition motif
    DK2256185T3|2014-12-08|Heterologous protection against Pasteurella multocida, using the P. multocida fur cells and protein extracts of the outer membrane thereof
    JP2021132644A|2021-09-13|Purification of saccharide
    WO2019238757A1|2019-12-19|Escherichia coli o157:h7 proteins and uses thereof
    WO2019030271A1|2019-02-14|MULTI-FUNCTIONALIZED nOMV CONJUGATES
    BE1022553A1|2016-05-31|MUTANTS OF SPY0269
    同族专利:
    公开号 | 公开日
    EP3140414A1|2017-03-15|
    SG11201609132TA|2016-11-29|
    WO2015169774A1|2015-11-12|
    US20170073716A1|2017-03-16|
    US10150979B2|2018-12-11|
    BE1022780A1|2016-09-02|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO2001068903A1|2000-03-16|2001-09-20|The Children's Hospital Of Philadelphia|Modulating production of pneumococcal capsular polysaccharide|
    WO2006065137A2|2004-12-16|2006-06-22|Stichting Top Institute Food And Nutrition|Novel efficient production process for capsular polysaccharides of pathogenic grampositive bacteria by heterologous expression and secretion of complex polysaccharides in non-pathogenic, non-invasive gram- positive bacteria|
    EP3034516A1|2014-12-19|2016-06-22|Novartis AG|Purification of streptococcal capsular polysaccharide|
    EP3292146A1|2015-05-04|2018-03-14|Pfizer Inc|Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    EP14167448|2014-05-07|
    EP14167448.1|2014-05-07|
    [返回顶部]